Physician profile
Allen Lieberman
NPI 1922075787
$38,731.17
in general payments reported to CMS, 2019-2025
17 companies · $8,484 in 2025
The $8,484 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,721 · 2021: $5,918 · 2022: $432 · 2023: $372 · 2024: $267 · 2025: $8,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Food and Beverage: $1,729 · Consulting Fee: $1,700 · Travel and Lodging: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Food and Beverage | $1,729.36 |
| Consulting Fee | $1,700.00 |
| Travel and Lodging | $494.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24,891.81 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $5,539.33 | 2025 | Neffy |
| Genzyme Corporation | $4,554.74 | 2019-2025 | |
| Kaleo, INC. | $2,656.19 | 2019-2025 | Auvi-Q |
| Genentech USA, INC. | $277.45 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $251.46 | 2019-2025 | Tezspire, Daliresp, Airsupra |
| Glaxosmithkline, LLC. | $184.92 | 2021-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $162.78 | 2019-2025 | |
| Phadia US INC. | $57.25 | 2020-2022 | |
| Alk-Abello, INC | $44.13 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $38.30 | 2022-2023 | Tezspire |
| Medtronic, INC. | $21.17 | 2025 | Propel |
| Takeda Pharmaceuticals U.S.A., INC. | $20.91 | 2024 | Eohilia |
| Aimmune Therapeutics, INC. | $18.90 | 2021 | |
| Organon LLC | $11.83 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.